Benefits
Peak expiratory flow improved in one small asthma trial
In the one fully published trial — 56 days at 200 mg/day in adults with mild-to-moderate asthma — peak expiratory flow rate rose more in the supplement group than on placebo (+90.0 vs +43.9 L/min from baseline, p=0.019). Note that the placebo group improved by roughly half as much on its own. FEV1 was measured in the same trial and did not differ significantly between the groups (+0.05 L vs −0.03 L, p=0.41). The widely repeated FEV1 up to 16% figure comes from a second study in 105 adults reporting air-pollution sensitivity that exists only as a 2023 conference abstract; the abstract reports that the supplement arms beat placebo on lung-function measures (p<0.05), but the full data, including the size of the placebo response, have never been published.
Lung capacity (FVC) — figure from a conference abstract only
The supplier reports that forced vital capacity improved by up to 30% in a 42-day study of 105 adults who report sensitivity to air pollution. That study has so far appeared only as a 2023 conference abstract and poster rather than as a full peer-reviewed paper; 'up to' describes a best case rather than an average; and no placebo-group value or outcome-by-outcome statistics have been released. FVC was not among the outcomes reported in the fully published trial of this blend, so this number should be read as a manufacturer figure that cannot be independently checked.
Six-minute walk distance — figure from a conference abstract only
The supplier reports a 6-minute walk test improvement of up to 7% in the same 42-day study of 105 pollution-sensitive adults. The 6-minute walk test is a validated submaximal exercise measure, and the conference abstract states that the supplement arms beat placebo (p<0.05), but without a full published report there is no way to check the actual distances walked, what the placebo group achieved, or how the up-to-7% figure was derived. No fully published trial of this blend has measured exercise capacity.
Breathing comfort and daily-life scores in a small clinical trial
In a 56-day double-blind placebo-controlled trial in adults with mild-to-moderate asthma (36 randomized, 29 completed), the supplement group improved more than placebo on all four domains of the Asthma Quality of Life Questionnaire — which was the trial's primary endpoint — with emotional function (p=0.0305) and symptom score (p=0.0002) separating by day 14. The participants were people under medical care for a diagnosed respiratory condition rather than healthy adults, the trial was funded by the manufacturer, and 29 completers is a very small basis for any conclusion. This ingredient is not a treatment for asthma or any other disease.
Immune biomarker modulation (IFN-γ up, IL-4 down)
In the published asthma trial, serum IFN-γ rose (22.0 vs 15.4 pg/ml, p=0.0014) and IL-4 fell (1.09 vs 1.44 pg/ml, p=0.0497) versus placebo over 56 days. These are laboratory markers of Th1/Th2 balance measured in 29 people with asthma — not measures of how often anyone got sick or how long illness lasted. The supplier also reports changes in CD4+ T helper cell percentage and in IL-8 in the 105-person pollution-sensitivity study, but that study has appeared only as a 2023 conference abstract, so those figures cannot be independently checked.
Upper respiratory symptoms (WURSS-21) — conference abstract only
The supplier reports up to about a 40% reduction in upper respiratory tract symptoms on the Wisconsin Upper Respiratory Symptom Survey (WURSS-21) in the 42-day study of 105 pollution-sensitive adults. WURSS-21 is a validated patient-reported questionnaire, and the conference abstract reports that symptom scores improved against placebo, but the study has never been published in full and no placebo-group value has been released. The only peer-reviewed trial of this blend measured asthma-related quality of life, not cold or flu symptoms. Treat the figure as a manufacturer claim.
Psychological well-being (PGWBI) — conference abstract only
The supplier reports that Psychological General Well-Being Index scores improved by up to 18% in the 42-day study of 105 pollution-sensitive adults, which has appeared only as a 2023 conference abstract; no comparison figure for the placebo group has been released. The published asthma trial did find a significant improvement over placebo on the emotional function domain of a quality-of-life questionnaire (p=0.0305), which is a narrower finding than a general mood or well-being benefit.
5-LOX inhibition in laboratory testing
In a cell-free enzyme assay, the 1:1 blend inhibited 5-lipoxygenase at a lower concentration than either extract on its own: mean IC50 11.6 µg/ml for the blend versus 14.8 µg/ml for the Boswellia extract (p=0.0135) and 22.1 µg/ml for the Aegle marmelos extract (p<0.0001). The blend also lowered 5-LOX and FLAP protein levels in cultured human monocytes. 5-LOX generates leukotrienes, which contribute to airway inflammation. All of this was measured in test tubes and cell culture — 5-LOX activity has never been measured in people taking this ingredient, and a laboratory enzyme result does not establish a clinical effect.
Mechanism of action
5-Lipoxygenase (5-LOX) inhibition
AKBA from Boswellia serrata is one of the most well-characterized natural 5-LOX inhibitors. 5-LOX produces leukotrienes (LTB4, LTC4) that drive airway inflammation, bronchoconstriction, and mucus production. Zileuton, a prescription drug, inhibits the same enzyme. A shared pathway does not mean a botanical extract produces comparable effects, and the comparison for this blend has only been made in laboratory assays and in a rat airway-inflammation model.
Synergistic Boswellia + Aegle activity
In an isolated-enzyme assay the 1:1 combination inhibited 5-LOX at a lower concentration (mean IC50 11.6 µg/ml) than the Boswellia gum resin extract (14.8 µg/ml, p=0.0135) or the Aegle marmelos fruit extract (22.1 µg/ml, p<0.0001) on its own. The difference is modest and was seen only in vitro; whether it translates into anything measurable in a person taking 200 mg/day has not been tested, and no human study of this blend has measured 5-LOX activity or leukotriene levels.
Th1/Th2 cytokine balance shift
AlvioLife increases IFN-γ (a Th1 cytokine) and reduces IL-4 (a Th2 cytokine), shifting immune balance away from the allergic Th2-skewed pattern associated with asthma and allergic respiratory conditions. Whether that shift reduces airway responsiveness in people taking the ingredient was not measured. The cytokine changes and the symptom-score changes were recorded in the same 29-completer trial, which cannot show that one caused the other.
CD4+ T helper cell modulation
The supplier reports a change in CD4+ T helper cell percentage in the 105-person pollution-sensitivity study, which so far exists only as a 2023 conference abstract. The direction and size of that change have not been published in full, and a shift in a cell-count percentage is not by itself evidence of better immune function.
IL-8 inflammation reduction
The supplier reports a reduction in the inflammatory chemokine IL-8 in the 105-person pollution-sensitivity study, so far published only as a 2023 conference abstract. IL-8 recruits neutrophils to inflamed tissue, so a reduction is a plausible anti-inflammatory signal, but the underlying data have not been published in full and no effect on lung tissue has been demonstrated in people.
Clinical trials
A 42-day randomized, double-blind, placebo-controlled study in 105 adults aged 20-65 who reported sensitivity to air pollution, with three arms: AlvioLife 200 mg/day; AlvioLife 200 mg/day plus 200 mg licorice extract (Glycyrrhiza glabra); and placebo. Outcomes included lung function (FEV1), lung capacity (FVC), 6-minute walk test, WURSS-21 upper respiratory symptoms, PGWBI well-being, and CD4+ and IL-8 biomarkers. The results were presented at the 2023 American Society for Nutrition meeting and published as a conference abstract and poster; a full peer-reviewed paper has not appeared and the study is not indexed in PubMed, so the outcome-by-outcome data cannot be independently checked.
105 adults aged 20-65 reporting sensitivity to air pollution, randomized to three arms. 42-day intervention.
As reported by the supplier: FEV1 up to 16%, FVC up to 30%, 6-minute walk up to 7%, WURSS-21 upper respiratory symptoms reduced by up to about 40%, PGWBI well-being up to 18%, perceived immune status improved by week 3, plus changes in CD4+ T helper cells and IL-8. The conference abstract states that both supplement arms improved on the respiratory and walking measures compared with placebo at 21 and 42 days (p<0.05), but every headline figure here is an up-to number released without a placebo-group value or an outcome-by-outcome effect size, and the full study has never been published or independently reviewed. An up-to number describes a best case, not an average. Health Canada reviewed this company-submitted study and licensed specified respiratory-health claims for the Canadian market, which authorizes Canadian label wording rather than independently confirming these percentages.
Double-blind placebo-controlled trial of AlvioLife (LI13109F) at 200 mg/day for 56 days in adults with mild-to-moderate asthma; registered as CTRI/2016/10/007393 and published in Phytotherapy Research 2018;32(1):140-150 (doi: 10.1002/ptr.5963; PMID 29210124). Authors: Yugandhar P, Rao KM, Sengupta K. Funded by Laila Nutraceuticals, the manufacturer, with one author based at its R&D centre. The primary endpoint was the Asthma Quality of Life Questionnaire; lung function and serum cytokines were secondary endpoints.
36 adults with mild-to-moderate asthma randomized (18 per arm); 29 completed the study (16 supplement, 13 placebo). 56-day intervention.
All four Asthma Quality of Life Questionnaire domains improved more than placebo at day 56, and emotional function (p=0.0305) and symptom score (p=0.0002) separated from placebo by day 14. Peak expiratory flow rose 90.0 L/min from baseline versus 43.9 L/min on placebo (p=0.019) — the placebo group gained roughly half as much on its own. FEV1 did not differ significantly between the groups (+0.05 L versus −0.03 L, p=0.41). Serum IFN-γ rose (p=0.0014) and IL-4 fell (p=0.0497). Minor gastrointestinal upset, mild fever and general weakness occurred in both groups, evenly distributed, with no serious adverse events. With 29 completers, uneven dropout and manufacturer funding, this is preliminary evidence obtained in a diagnosed patient group.
This entry is background, not a study of AlvioLife. Boswellic acids, and AKBA in particular, inhibit 5-lipoxygenase in laboratory assays, and Boswellia gum resin has long traditional use in Ayurveda. Trials of other Boswellia preparations used different extracts, doses and standardizations from AlvioLife, so their results do not transfer to this product.
Not applicable — background literature on Boswellia extracts generally, not a study of this ingredient.
AKBA-rich Boswellia extracts inhibit 5-LOX in laboratory assays. For breathing specifically the evidence base is thin: a 1998 double-blind study gave 900 mg/day of plain Boswellia gum resin to 40 adults with asthma and reported improvement in 70% versus 27% on placebo, and a 2010 systematic review of 26 herbal asthma trials listed that study among a handful showing potential to improve lung function — but the same review concluded that symptom improvements were not strongly supported by objective measures, that most trials were small, short and methodologically poor, and that no recommendation for herbal treatment of asthma could be made from the available evidence. AlvioLife is a different preparation at a different dose: the finished blend is standardized to 15% AKBA and 0.3% imperatorin, its Boswellia component being a 30% AKBA extract blended 1:1 with an Aegle marmelos fruit extract, and it is taken at 200 mg/day. None of that earlier work is direct evidence for it.